KR20210018906A - Anca 연관 혈관염에 대한 c5a 길항제의 투여 및 효과 - Google Patents

Anca 연관 혈관염에 대한 c5a 길항제의 투여 및 효과 Download PDF

Info

Publication number
KR20210018906A
KR20210018906A KR1020217000253A KR20217000253A KR20210018906A KR 20210018906 A KR20210018906 A KR 20210018906A KR 1020217000253 A KR1020217000253 A KR 1020217000253A KR 20217000253 A KR20217000253 A KR 20217000253A KR 20210018906 A KR20210018906 A KR 20210018906A
Authority
KR
South Korea
Prior art keywords
treatment
level
complement factor
administering
abaccopan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217000253A
Other languages
English (en)
Korean (ko)
Inventor
준 뎅
페트루스 베커
잔 힐슨
Original Assignee
케모센트릭스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 케모센트릭스, 인크. filed Critical 케모센트릭스, 인크.
Priority to KR1020267004102A priority Critical patent/KR20260027358A/ko
Publication of KR20210018906A publication Critical patent/KR20210018906A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020217000253A 2018-06-07 2019-06-06 Anca 연관 혈관염에 대한 c5a 길항제의 투여 및 효과 Ceased KR20210018906A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020267004102A KR20260027358A (ko) 2018-06-07 2019-06-06 Anca 연관 혈관염에 대한 c5a 길항제의 투여 및 효과

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862682013P 2018-06-07 2018-06-07
US62/682,013 2018-06-07
PCT/US2019/035758 WO2019236820A1 (en) 2018-06-07 2019-06-06 Dosing and effect of c5a antagonist with anca-associated vasculitis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020267004102A Division KR20260027358A (ko) 2018-06-07 2019-06-06 Anca 연관 혈관염에 대한 c5a 길항제의 투여 및 효과

Publications (1)

Publication Number Publication Date
KR20210018906A true KR20210018906A (ko) 2021-02-18

Family

ID=68764799

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217000253A Ceased KR20210018906A (ko) 2018-06-07 2019-06-06 Anca 연관 혈관염에 대한 c5a 길항제의 투여 및 효과
KR1020267004102A Pending KR20260027358A (ko) 2018-06-07 2019-06-06 Anca 연관 혈관염에 대한 c5a 길항제의 투여 및 효과

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020267004102A Pending KR20260027358A (ko) 2018-06-07 2019-06-06 Anca 연관 혈관염에 대한 c5a 길항제의 투여 및 효과

Country Status (15)

Country Link
US (2) US11191756B2 (enExample)
EP (1) EP3801519A4 (enExample)
JP (2) JP2021527062A (enExample)
KR (2) KR20210018906A (enExample)
CN (1) CN112423752A (enExample)
AU (1) AU2019282327B2 (enExample)
BR (1) BR112020024842A2 (enExample)
CA (1) CA3102403A1 (enExample)
CL (1) CL2020003171A1 (enExample)
IL (1) IL279188B2 (enExample)
MA (1) MA52808A (enExample)
MX (1) MX2020013166A (enExample)
SG (1) SG11202011961YA (enExample)
WO (1) WO2019236820A1 (enExample)
ZA (1) ZA202007615B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021527062A (ja) 2018-06-07 2021-10-11 ケモセントリックス，インコーポレイティド ＡＮＣＡ関連血管炎に対するｃ５ａアンタゴニストの投薬及び効果
CN113164403A (zh) 2018-11-30 2021-07-23 凯莫森特里克斯股份有限公司 胶囊制剂
AU2020380367B2 (en) 2019-11-08 2026-06-04 Chemocentryx, Inc. Salt forms of a complement component C5a receptor
KR20220098754A (ko) 2019-11-08 2022-07-12 케모센트릭스, 인크. 보체 성분 C5a 수용체의 비정질 형태
WO2026157730A1 (en) * 2025-01-21 2026-07-30 Metagone Biotech Inc. Compositions and methods for treatment of macular degeneration and geographic atrophy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1739078A1 (de) 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
CN101611008A (zh) * 2006-12-22 2009-12-23 恩希赛弗制药公司 C3a受体调节剂及其使用方法
CA2714296A1 (en) * 2008-02-20 2009-08-27 G2 Inflammation Pty Ltd Humanized anti-c5ar antibodies
JP5819730B2 (ja) 2008-12-22 2015-11-24 ケモセントリックス，インコーポレイティド Ｃ５ａＲアンタゴニスト
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
DK2585064T3 (en) 2010-06-24 2017-07-24 Chemocentryx Inc C5aR antagonists
JP6898229B6 (ja) 2014-09-29 2021-07-28 ケモセントリックス，インコーポレイティド Ｃ５ａＲアンタゴニスト製造における方法及び中間体
EP3283889B1 (en) 2015-04-17 2020-02-26 Euroimmun Medizinische Labordiagnostika AG Method and assay for diagnosing rapidly progressive glomerulonephritis in a subject
SG11201808625QA (en) 2016-04-04 2018-10-30 Chemocentryx Inc SOLUBLE C5aR ANTAGONISTS
KR20200109297A (ko) 2017-10-31 2020-09-22 케모센트릭스, 인크. 소변 sCD163의 C5aR 억제제 감소
JP2021527062A (ja) 2018-06-07 2021-10-11 ケモセントリックス，インコーポレイティド ＡＮＣＡ関連血管炎に対するｃ５ａアンタゴニストの投薬及び効果

Also Published As

Publication number Publication date
EP3801519A4 (en) 2022-03-30
MA52808A (fr) 2021-04-14
CA3102403A1 (en) 2019-12-12
US11191756B2 (en) 2021-12-07
CN112423752A (zh) 2021-02-26
EP3801519A1 (en) 2021-04-14
CL2020003171A1 (es) 2021-06-04
SG11202011961YA (en) 2020-12-30
IL279188A (en) 2021-01-31
JP2021527062A (ja) 2021-10-11
US20190374524A1 (en) 2019-12-12
WO2019236820A1 (en) 2019-12-12
IL279188B1 (en) 2025-12-01
ZA202007615B (en) 2024-05-30
KR20260027358A (ko) 2026-02-27
IL279188B2 (en) 2026-04-01
AU2019282327A1 (en) 2021-01-07
AU2019282327B2 (en) 2025-04-24
US12350263B2 (en) 2025-07-08
BR112020024842A2 (pt) 2021-03-02
US20220296576A1 (en) 2022-09-22
MX2020013166A (es) 2021-03-29
JP2024114706A (ja) 2024-08-23

Similar Documents

Publication Publication Date Title
JP2024114706A (ja) ＡＮＣＡ関連血管炎に対するｃ５ａアンタゴニストの投薬及び効果
Kardaun et al. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis
ES3026359T3 (en) Ccx168 for use in the treatment of c3 glomerulopathy
AU2014234992B2 (en) Methods for treating inflammation, autoimmune disorders and pain
EA028343B1 (ru) Лечение дегенеративного заболевания сустава
JP2023500919A (ja) 関節炎の処置
JP2015513359A (ja) 座瘡の排除又は予防用のピルフェニドンと改変ジアリルジスルフィド酸化物（ｍ−ｄｄｏ）とを含む半固形局所組成物
CN104224772A (zh) 一种包含丁苯酞和冰片的药物组合物及其应用
AU2015321365A1 (en) A combination of kynurenine and antigen presenting cells (APC) as therapeutics and methods for their use in immune modulation
KR20160128990A (ko) 피부에서 외부 자극에 대한 반응을 진정시키기 위한 제제 및 이러한 반응을 진정시키는 방법
RU2835509C2 (ru) Дозирование и эффект c5a антагониста при anca-ассоциированном васкулите
JP7361448B2 (ja) トランスグルタミナーゼ発現促進剤
ES2932076T3 (es) Moduladores agonistas de los receptores de glucocorticoides selectivos (SEGRAM) no esteroideos y usos de los mismos
EP4403164A1 (en) Gel composition for prevention or treatment of atopic dermatitis
CN113474001A (zh) 包含香蜂花叶提取物的馏分的药物组合物
EP2714706A1 (fr) Sucroses octasulfates de calcium, leur préparation et leurs applications pharmaceutiques et cosmétiques
US20240269138A1 (en) Mmp13 as a therapeutic target for allergic inflammatory diseases
US6919088B2 (en) Water-soluble stable salts of petroselinic acid
KR20260023197A (ko) 세사민을 포함하는 아토피성 피부염의 개선 또는 치료용 조성물
WO2025064402A1 (en) Method for treating sickle cell disease by targeting senescent cells
WO2024256849A1 (en) 4-phenylbutyric acid derivatives for use in the treatment of fibrosis
US20130123365A1 (en) Use of fts and analogs to treat non-autoimmune-allergic and non-allergic inflammatory conditions
EP3030250A1 (de) Intraartikuläre applikation von pepstatin bei arthrose
KR20150058836A (ko) 대체경로 억제제를 함유하는 신장 질환 예방 또는 치료용 조성물 및 이를 이용한 신장 질환 예방 또는 치료방법
HK40068309A (en) Treatment of arthritis

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

A18 Application divided or continuation or continuation in part accepted

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A18-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

V11 Administrative appeal requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-V10-V11-APL-PJ0201 (AS PROVIDED BY THE NATIONAL OFFICE)